Nanomedicines for targeted delivery of etoposide to non-small cell lung cancer using transferrin functionalized nanoparticles

RSC Advances ◽  
2015 ◽  
Vol 5 (61) ◽  
pp. 49122-49131 ◽  
Author(s):  
Deep Pooja ◽  
Hitesh Kulhari ◽  
Lakshmi Tunki ◽  
Srinivas Chinde ◽  
Madhusudana Kuncha ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Targeted Delivery ◽  
Plasma Concentrations ◽  
Lipid Nanoparticles ◽  
Small Cell ◽  
Small Cell Lung ◽  
Sustained Drug Release ◽  
Functionalized Nanoparticles

Tf-conjugated solid lipid nanoparticles were designed for selectively targeting etoposide to human non-small cell lung cancer resulting in sustained drug release, improved plasma concentrations and accumulation of etoposide in targeted lung tissues.

PD-L1 Gene Polymorphism and High Level of Plasma Soluble Pd-L1 Protein may be aSsociated with Non-Small Cell Lung Cancer

2015 ◽  
Vol 30 (4) ◽  
pp. 364-368 ◽  
Author(s):  
Sensen Cheng ◽  
Jinsong Zheng ◽  
Jingyan Zhu ◽  
Chao Xie ◽  
Xia Zhang ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Plasma Levels ◽  
Plasma Concentrations ◽  
Small Cell ◽  
Small Cell Lung ◽  
High Level ◽  
Nsclc Patients ◽  
L1 Protein

Background PD-1 and its ligand PD-L1 belong to the co-inhibition molecules, which can downregulate immune responses. The PD-L1 polymorphism and the level of soluble PD-L1 (sPD-L1) were investigated in non-small cell lung cancer (NSCLC). Methods A total of 288 NSCLC patients and 300 controls were enrolled. An A/C polymorphism at position 8923 in the PD-L1 gene was genotyped using the polymerase chain reaction-restriction fragment length polymorphism method. Results The prevalence of the 8923C allele was significantly higher in NSCLC patients than controls (10.2% versus 5.3%, p = 0.002, odds ratio 2.03, 95% confidence interval 1.30-3.17; data were adjusted for age and sex). NSCLC patients also showed increased plasma levels of sPD-L1 compared to controls (1.92 ng/mL versus 0.91 ng/mL, p<0.001). Furthermore, lung adenocarcinoma patients had higher sPD-L1 levels than patients with squamous cell carcinoma (p<0.01). However, no association was observed between the different genetic variants and plasma concentrations of sPD-L1. Conclusions The PD-L1 8923A/C polymorphism could be associated with increased susceptibility to NSCLC. Plasma levels of sPD-L1 are significantly increased in NSCLC patients, especially those with adenocarcinoma.

TRAIL-coated lipid-nanoparticles overcome resistance to soluble recombinant TRAIL in non-small cell lung cancer cells

2016 ◽  
Vol 27 (18) ◽  
pp. 185101 ◽  
Author(s):  
Diego De Miguel ◽  
Ana Gallego-Lleyda ◽  
José María Ayuso ◽  
Sandra Erviti-Ardanaz ◽  
Roberto Pazo-Cid ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cancer Cells ◽  
Cell Lung Cancer ◽  
Lipid Nanoparticles ◽  
Small Cell ◽  
Lung Cancer Cells ◽  
Small Cell Lung ◽  
Recombinant Trail

scholarly journals Axl-Targeted Delivery of the Oncosuppressor miR-137 in Non-small-Cell Lung Cancer

2019 ◽  
Vol 17 ◽  
pp. 256-263 ◽  
Author(s):  
Silvia Nuzzo ◽  
Silvia Catuogno ◽  
Maria Capuozzo ◽  
Alfonso Fiorelli ◽  
Piotr Swiderski ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Targeted Delivery ◽  
Small Cell ◽  
Small Cell Lung

Phase I/II and pharmacologic study of long-term continuous infusion etoposide combined with cisplatin in patients with advanced non-small-cell lung cancer.

1994 ◽  
Vol 12 (1) ◽  
pp. 83-89 ◽  
Author(s):  
H Kunitoh ◽  
K Watanabe
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Continuous Infusion ◽  
Cell Lung Cancer ◽  
Performance Status ◽  
Plasma Concentrations ◽  
Primary Objective ◽  
Small Cell ◽  
Small Cell Lung

PURPOSE The primary objective of this study was to determine the pharmacodynamics of prolonged administration of low-dose etoposide by continuous infusion (CI). We investigated the hypothesis that maintenance of an etoposide concentration of 1 microgram/mL would be cytotoxic in non-small-cell lung cancer (NSCLC). PATIENTS AND METHODS Thirty patients with advanced NSCLC without prior chemotherapy or radiotherapy were treated with etoposide at 20, 25, or 30 mg/m2/d infused continuously for 14 days (336 hours), following a 10-mg/m2 bolus. They also received cisplatin 30 mg/m2 on chemotherapy days 1, 2, and 3. Plasma concentrations of etoposide were measured by high-performance liquid chromatography at 0, 2, 4, 24, 48, 120, 336, and 342 hours after initiation of CI etoposide. RESULTS The maximum-tolerated dose (MTD) of etoposide was 25 mg/m2/d with leukocytopenia as the dose-limiting toxicity. Plasma concentrations of etoposide at steady-state (Css) showed approximately twofold interpatient variability at each dose level, and were greater than 1 microgram/mL in most patients at higher dose levels. The severity of neutropenia was dependent on performance status (PS), age, and the Css of etoposide. The overall response rate for the 29 assessable cases was 28%. Five of 11 patients with a Css greater than 1.2 micrograms/mL responded to the therapy, whereas only one of 10 patients with a Css less than 1 microgram/mL responded. CONCLUSION With long-term CI of etoposide, a Css greater than 1 or 1.2 micrograms/mL appeared necessary, but not sufficient, to achieve a major response against NSCLC.

Microparticles containing erlotinib-loaded solid lipid nanoparticles for treatment of non-small cell lung cancer

2017 ◽  
Vol 43 (8) ◽  
pp. 1244-1253 ◽  
Author(s):  
Zahra Bakhtiary ◽  
Jaleh Barar ◽  
Ayuob Aghanejad ◽  
Amir Ata Saei ◽  
Elhameh Nemati ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Solid Lipid Nanoparticles ◽  
Lipid Nanoparticles ◽  
Small Cell ◽  
Small Cell Lung ◽  
Solid Lipid
Sign in / Sign up

Export Citation Format

Share Document